- Ticker
- ACOR
- Price
- 1.20
- Stock movement down
- -0.15 (-11.11%)
- Company name
- Acorda Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers-Specialty & Generic
- Market cap
- 29.21M
- Ent value
- 293.64M
- Price/Sales
- 0.17
- Price/Book
- 0.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -35.14%
- 1 year return
- 132.74%
- 3 year return
- -37.00%
- 5 year return
- -56.66%
- 10 year return
- -40.90%
Last updated: 2024-04-08
DIVIDENDS
ACOR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.17 |
| Price to Book | 0.31 |
| EV to Sales | 1.71 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 24.34M |
| EPS (TTM) | -6.96 |
| FCF per share (TTM) | -3.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 172.15M |
| Gross profit (TTM) | 127.05M |
| Operating income (TTM) | -105.09M |
| Net income (TTM) | -137.12M |
| EPS (TTM) | -6.96 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 73.80% |
| Operating margin (TTM) | -61.05% |
| Profit margin (TTM) | -79.65% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.54M |
| Net receivables | 13.87M |
| Total current assets | 82.11M |
| Goodwill | 0.00 |
| Intangible assets | 305.09M |
| Property, plant and equipment | 0.00 |
| Total assets | 395.60M |
| Accounts payable | 9.81M |
| Short/Current long term debt | 172.92M |
| Total current liabilities | 37.95M |
| Total liabilities | 301.97M |
| Shareholder's equity | 93.62M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -62.71M |
| Capital expenditures (TTM) | 312.00K |
| Free cash flow (TTM) | -63.02M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -146.46% |
| Return on Assets | -34.66% |
| Return on Invested Capital | -144.08% |
| Cash Return on Invested Capital | -66.22% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.23 |
| Daily high | 1.37 |
| Daily low | 1.12 |
| Daily Volume | 262K |
| All-time high | 267.00 |
| 1y analyst estimate | 10.00 |
| Beta | 1.44 |
| EPS (TTM) | -6.96 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 2 May 2024 |
Downside potential
Loading...
Downside potential data
| ACOR | S&P500 | |
| Current price drop from All-time high | -99.55% | -0.85% |
| Highest price drop | -99.90% | -56.47% |
| Date of highest drop | 29 Sep 2022 | 9 Mar 2009 |
| Avg drop from high | -48.91% | -11.35% |
| Avg time to new high | 71 days | 13 days |
| Max time to new high | 2316 days | 1805 days |
COMPANY DETAILS
Marketcap
29.21M
Marketcap category
Small-cap
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Employees
111
Website
Investor relations
-
SEC filings
CEO
Ronald Cohen
Country
USA
City
Ardsley
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner